Dianthus Therapeutics Inc [DNTH] stock is trading at $21.09, up 15.56%. An important factor to consider is whether the stock is rising or falling in short-term value. The DNTH shares have gain 17.43% over the last week, with a monthly amount glided 11.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 03, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $48 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $58 on July 26, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight. H.C. Wainwright started tracking with a Buy rating for this stock on May 16, 2024, and assigned it a price target of $40. In a note dated February 15, 2024, Stifel initiated an Buy rating and provided a target price of $44 on this stock.
Dianthus Therapeutics Inc [DNTH] stock has fluctuated between $13.36 and $32.27 over the past year. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Dianthus Therapeutics Inc [NASDAQ: DNTH] shares were valued at $21.09 at the most recent close of the market. An investor can expect a potential return of 144.19% based on the average DNTH price forecast.
Analyzing the DNTH fundamentals
Dianthus Therapeutics Inc [NASDAQ:DNTH] reported sales of 6.52M for the trailing twelve months, which represents a growth of 33.07%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -17.96%, Pretax Profit Margin comes in at -15.44%, and Net Profit Margin reading is -15.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.29 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.54 points at the first support level, and at 16.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.50, and for the 2nd resistance point, it is at 25.92.
Ratios To Look Out For
For context, Dianthus Therapeutics Inc’s Current Ratio is 15.99. On the other hand, the Quick Ratio is 15.99, and the Cash Ratio is 0.6. Considering the valuation of this stock, the price to sales ratio is 104.03, the price to book ratio is 2.06.
